Valuation: Rezolute, Inc.

Market Cap 490M 424M 396M 363M 683M 46.63B 694M 4.64B 1.82B 23.37B 1.84B 1.8B 77.27B P/E 2026 *
-6.7x
P/E 2027 * -7.22x
Enterprise Value 490M 424M 396M 363M 683M 46.63B 694M 4.64B 1.82B 23.37B 1.84B 1.8B 77.27B EV / Sales 2026 *
-
EV / Sales 2027 * 213x
Free-Float
89.84%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Rezolute, Inc.

1 day-0.21%
1 week-0.64%
Current month-0.64%
1 month-5.44%
3 months+46.11%
6 months+50.32%
Current year+98.73%
1 week 4.51
Extreme 4.51
5.25
1 month 4.14
Extreme 4.14
5.4
Current year 1.87
Extreme 1.87
5.42
1 year 1.07
Extreme 1.07
11.46
3 years 0.72
Extreme 0.72
11.46
5 years 0.72
Extreme 0.72
11.75
10 years 0.72
Extreme 0.72
100
Manager TitleAgeSince
Chief Executive Officer 58 30/01/2013
Director of Finance/CFO 52 23/01/2024
Chief Operating Officer - -
Director TitleAgeSince
Chairman 58 04/05/2022
Director/Board Member 55 20/11/2019
Chairman 68 10/02/2019
Date Insider Type Main position Quantity % Market Cap.
7/2/26 A Tax

Chief Technology Officer

-3,062 0.0035%
7/2/26 A Tax

Chief Financial Officer

-3,062 0.0035%
7/2/26 A Tax

Chief Executive Officer

-8,004 0.0092%
Change 5-day change 1-year change 3-year change Capi.($)
-0.21%-0.64%-19.28%+194.97% 490M
+8.49%+20.55%+70.77%+110.32% 68.12B
+1.25%+2.44%+34.27%+70.43% 55.18B
-1.09%+32.96%+19.67%+494.56% 28.63B
+10.83%+18.38%+56.20%+6.03% 23.99B
+2.72%+3.41%-16.11%-7.96% 23.53B
+6.50%+7.56%+44.65%-21.73% 18.45B
+6.20%+11.51%+33.87%+693.38% 16.44B
-3.88%+16.98%+199.30%+359.77% 15.83B
+3.58%+1.96%+43.35%+163.76% 13.4B
Average +3.44%+10.45%+46.67%+206.35% 26.4B
Weighted average by Cap. +4.35%+13.07%+50.56%+168.52%

Financials

2026 *2027 *
Net sales - 2.3M 1.99M 1.86M 1.71M 3.21M 219M 3.26M 21.84M 8.57M 110M 8.65M 8.46M 363M
Net income -72.7M -62.88M -58.72M -53.87M -101M -6.92B -103M -689M -270M -3.47B -273M -267M -11.46B -75.12M -64.98M -60.68M -55.66M -105M -7.15B -106M -712M -279M -3.58B -282M -276M -11.85B
Net Debt - -
Logo Rezolute, Inc.
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Employees
68
Date Price Change Volume
07/08/26 $4.690 -0.21% 986,260
06/08/26 $4.700 +0.43% 924,974
05/08/26 $4.680 -5.84% 1,374,275
04/08/26 $4.970 +1.22% 2,541,360
03/08/26 $4.910 +4.03% 1,428,173
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.690USD
Average target price
7.667USD
Spread / Average Target
+63.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RZLT Stock